key: cord-0931595-bbdxjez5
authors: Dawre, Shilpa; Maru, Saurabh
title: Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment
date: 2021-04-26
journal: Life Sci
DOI: 10.1016/j.lfs.2021.119561
sha: 58e1a5f3872601fe52051732616a495141825df1
doc_id: 931595
cord_uid: bbdxjez5

Respiratory viral infections are major cause of highly mortal pandemics. They are impacting socioeconomic development and healthcare system globally. These emerging deadly respiratory viruses develop newer survival strategies to live inside host cells and tricking the immune system of host. Currently, medical facilities, therapies and research –development teams of every country kneel down before novel corona virus (SARS-CoV-2) which claimed ~2,828,629 lives till date. Thus, there is urgent requirement of novel treatment strategies to combat against these emerging respiratory viral infections. Nanocarriers come under the umbrella of nanotechnology and offer numerous benefits compared to traditional dosage forms. Further, unique physicochemical properties (size, shape and surface charge) of nanocarriers provide additional advantage for targeted delivery. This review discusses in detail about the respiratory viruses, their transmission mode and cell invasion pathways, survival strategies, available therapies, and nanocarriers for the delivery of therapeutics. Further, the role of nanocarriers in the development of treatment therapy against SARS-CoV-2 is also overviewed.

single-stranded RNA genome in a helical nucleocapsid. This virus fuse with cell by interaction between sialic acid present on cell surface and glycoproteins neuraminidase, hemagglutinin esterase and hemagglutinin [21] . Further, the glycosylated receptor-binding protein (RBP) and the glycosylated fusion (F) protein is also present. The HPIV 1 is a common cause of laryngotracheobronchitis, mostly in infants (0.5 to 3 years). The symptoms are common cold following fever, cough, and hoarseness. Respiratory failure due to upper airway obstruction is not a usual but possibly a serious complication. However, the HPIV-2 can cause similar infections but complications are less severe and HPIV -3 may cause bronchiolitis and pneumonia in infants and immunocompromised host.

Human Metaneumovirus (HMPV) belongs to the family of viruses Paramyxoviridae and genus Metapneumovirus. The HMPV is classified into two lineages, A and B, and each group consists of no less than two subspecies (A1, A2, B1, and B2) [22] . It is enveloped, filamentous particles or spherical, pleomorphic (~209nm diameter) with a single-stranded RNA genome. It is the common cause of community spread of respiratory infection in adults and youngsters. The HMPV is responsible for shortness of breath, nasal congestion, cough, and fever and clinically infection leads to pneumonia and bronchitis.

Respiratory Adenovirus belongs to the genus Mastadenovirus, family Adenoviridae.

They are categorized into six groups (A, B, C, D, E, F, and G) with an additional 100 types identified to date. The indications of infection are of various type ranging from respiratory illness to diarrhea. Adenoviruses are non-enveloped, icosahedral virions (70 to 90 nm in diameter) containing double-stranded DNA (dsDNA). This icosahedral virion covered with fibers spread from each of the 12-penton base capsomers. These fibers have knobs which assist virus to attach on the host cells, cofactor proteins and monocyte chemoattractant protein (CD46 and MCP) and coxsackie and adenovirus receptor (CAR receptors) [23] . Mostly respiratory adenovirus utilizes only one type of receptors; however, subspecies D type of virus's usage both receptors concurrently. Adenoviruses most commonly cause cold that leads to croup, bronchitis, and pneumonia.

Human Bacovirus (HBOV) belongs to the family Parvoviridae, genus Bocavirus and J o u r n a l P r e -p r o o f subfamily Parvovirinae, The HBOV virions are non-enveloped and icosahedral particles (~25 nm diameter). The capsid includes a single-stranded DNA (ssDNA) genome and exhibit two capsid proteins (VP1 and VP2) with two nonstructural proteins (NP1 and NS1) [24] . The prevalence of HBOV was found globally and causes infections of the respiratory, intestinal epithelium, and lymphoid organs of children as well as adults in Asia, the Americas, Europe, Australia, and Africa [25] . [26] .

Novel coronavirus (SARS-CoV-2) also belongs to the family Coronaviridae. The SARS-CoV-2 is enveloped, spherical or pleomorphic virion enclosing single-stranded RNA with spike glycoproteins on its surface. Coronaviruses have four subspecies such as alpha, beta, gamma, and delta coronavirus. It exhibits several proteins viz. spike protein (S), membrane protein (M), envelope protein (E), nucleocapsid protein (N). Further, polyproteins PP1a, PP1ab proteases and nonstructural proteins (NSP1-NSP16) also present. Coronavirus is zoonotic and found in cats, pigs, dogs, and birds [27] . First SARS-CoV-2 positive case was identified and virus was isolated from a pneumonia patient from Wuhan, China in November, 2019. The clinical symptoms of SARS-CoV-2 are diverse, and from asymptomatic to symptomatic state including acute respiratory distress syndrome and multi-organ failure. Currently, WHO reported ~129,619,536 confirmed cases of COVID-19 including 2,827,610 deaths [28] .

The genome, family, subtypes, and structural features of respiratory viruses illustrated in Table   1 .

J o u r n a l P r e -p r o o f 

In general, respiratory viruses among humans transmit by three modes; indirect or direct interaction to diseased persons, via aerosols or droplets. Direct transmission takes place by straight contact from an infected person to a vulnerable individual (e.g. via contaminated hands) or indirect virus spreads through fomites. Respiratory viruses can also be transmitted through the air via aerosols and droplets. Droplets produced during sneezing, talking, or coughing do not linger in the air and move less than 1m before inhabiting the mucosa of close contacts or environmental surfaces. However, aerosols remain suspended in the air for a longer time and travel more due to slow settling velocity [29] . The accepted cut-off size amid the small aerosols 

Clathrin mediated endocytosis (CME) is the preferred and most studied route for internalization by viruses and is the key process for vesicular trafficking. This endocytosis process creates minute (60-200 nm) membrane vesicles that internalize a variety of cargo molecules from the plasma membrane of cells into the cytoplasm. The size and shape of viruses play a predominant role in entry through Clathrin mediated endocytosis. The viruses which infect animals mostly in the size ranging from 30 nm (parvoviruses) to 400 nm (poxviruses),

The mechanism of CME involves several sequential steps, which consist of: (1) HCoV-OC43), influenza virus, and human respiratory syncytial virus exploit caveolae-mediated endocytosis and lipid rafts to commute across the cell and transfer virions into another cell [39] .

The macropinocytosis is described as actin and growth factor induced transitory endocytic pathway that causes engulfment of a large amount of fluid with membrane into the vacuole. The process involves the development of macropinosomes when rearrangements of plasma membrane extensions occurred in outward-direction known as ruffles, while in other invasion pathways the membrane is invaginated and form a bud or pit into the cell [34] . The ruffle structure can be circular ruffles, blebs (large plasma membrane extrusions), or lamellipodia (planar folds). The formation of macropinosomes is not directed by any cytoplasmic coat/proteins, thus resulting in irregular size ruffles in size range of 0.5-10 μm. The mechanism involves various cellular components such as tyrosine kinases, cholesterol, serine/threonineprotein kinase PAK1, myosins, Ras-related C3 botulinum toxin substrate 1 (Rac1), cell division control protein 42 (Cdc42), Na+/H+ exchange, Ras-related protein Rab-3 (Rab3), C-terminalbinding protein 1, phosphatidylinositol 3-kinase, protein kinase C, actin, microtubules, Rasrelated protein 5 (Rab5), Ras-related protein Rab-7 (Rab7), and ADP-ribosylation factor 6 (Arf6) [40] .

Numerous viruses from diverse families take advantage of this macropinocytosis route either for direct entry or through an indirect pathway to support the infiltration of virions that may take entry by another endocytic pathway. Among the viruses that use this entry, the mechanism is the vaccinia virus, HIV type 1, rubella virus, and echovirus type 1. Amid respiratory viruses, human respiratory syncytial virus, respiratory adenovirus, and influenza virus make use of macropinocytosis for the cell infiltration [34, 41] . Besides, it was further observed that viruses use additional endocytic pathways to enter the cell but need macropinocytosis to support infiltration. The viruses which require macropinocytosis assistance for internalization are adenovirus 2/5 and SARS-CoV-2 [42] , [43] .

Phagocytosis (cell eating) is a mechanism of endocytosis different from J o u r n a l P r e -p r o o f macropinocytosis . The phagocytosis is used by particular cell types, as monocytes, dendritic   cells, and macrophages for the engulfment of big size foreign particles example bacteria. It   exhibits properties similar to macropinocytosis, comprising regulatory components, big vacuole size, actin dependency, cellular factors, and transient activation [44] . However, the molecular process is dissimilar; since attachment of foreign particle at the plasma membrane not only activates the phagocytosis process but also triggers the covering of particles by vacuoles formed by actin. Factors normally involved incorporating RhoA, actin, dynamin-2, tyrosine kinases, and cholesterol, Cdc42, AP2, Arf6, and Rac1. Phagocytosis is not a commonly used pathway for virus internalization. However, few viruses like herpes simplex virus 1, amoebal pathogen mimivirus, influenza virus, and RSV have reported entry by using phagocytosis mechanism [45] .

Along with the well-studied endocytic pathways discussed above, there is an indication of contribution of alternate or unusual pathway for the internalization of viruses. Internalization by these routes is independent of dynamin, actin, lipid rafts, clathrin, and caveolin, but necessitates cholesterol. Thus far, the viruses reported that use unusual or novel routes are lymphocytic choriomeningitis virus [46] , influenza A virus, human papillomavirus 16, and rotavirus. For instance, the influenza virus uses the novel entry routes corresponding with CME that provides supportive entry route; however, there is little information available.

Although understanding the unusual pathways of internalization is still not clear and incomplete. Cell biology literature still not describe how the viruses have been evolved to exploit novel endocytosis pathways. It will be very exciting to study these pathways and to recognize their functions and ligands. However, studies reported that there are mechanisms with which no virus entry has so far connected. These incorporate the flotillin pathway, the ADP-ribosylation factor 6 (Arf6) pathway, the glycosylphosphotidylinositol-anchored protein (GPI-AP) enriched compartments (GEEC) pathway, and the interleukin (IL-2) pathway [47] . The respiratory viruses' transmission mode, target cell, receptors of host cells, entry pathways, virus and host cell expressed proteins, pathogenesis, and symptoms are disclosed in Table 2 . 

The viruses are opportunistic pathogens; they can evolve several strategies to escape two barriers of a host that is the endosomal barrier and immune barrier [65] . They exhibit the inherent ability to adapt strategies under stress conditions to combat for their survival. These adaptive strategies facilitate them to impart superior protection against the host immune system and there by prolonging survival. Both enveloped and non-enveloped viruses develop several survival tactics; membrane fusion and pore formation are predominant [66] , [67] . In the following subsections, several strategies developed by respiratory viruses to survive and escape endosomal uptake or immune system are illustrated. The survival strategies, molecules involved in the process, and antiviral agents for treatment therapy act on specific survival pathway are enlisted in Table 3 .

The viruses evolved with fusion peptides, which attach to the endosomal membrane J o u r n a l P r e -p r o o f causes their destabilization. The fusogenic peptides constitute of short peptide domain of 20-30 amino acids [67] . Membrane fusion is a crucial process in cellular endocytosis and trafficking.

The majority of enveloped viruses exhibit single fundamental membrane peptides, which undergo conformational changes upon a trigger such as a change in pH. At acidic pH, fusogenic peptide undergoes structural changes from a hydrophilic coil to a hydrophobic helical [50] . This new-fangled α-helical conformation guides to the fusion of the viral membrane into the cellular membrane, resulting in disruption of the membrane and trafficking its genome into the cytoplasm. For example, Haemagglutinin is a peptide of the influenza virus coat, exhibits fusogenic activity [63] .

The other approach use by viruses to escape the endosomal barrier is pore formation. The formation of a pore is by the interrelationship between a line tension that seals the pore and membrane tension that broadens the pore. Some virus peptides have a high affinity for the edge of the pore. Attaching the peptide to the rim reduces the line tension resulting in instability in the pore radius and does not permit to seal it again. In an acidic environment, the protonation of the amino acid group of fusogenic peptide brings conformational changes [66] . As a result, the peptides adhere and self-assemble inside the phospholipid membrane in upright orientation to the plane of the membrane, hence creating pores. The 'Barrel-stave' model demonstrated the attachment of peptides with the membranes of endosomes and slowly their diffusion into the phospholipid layer. The respiratory viruses which use this strategy to invade the cells are human rhinoviruses [68] . Other viruses that use this mechanism are the vp1-Coxsackie virus and poliovirus [67] .

Viruses have developed a tactic to transform the membrane of endosomes by the enzymatic actions of either virus or host-encoded enzymes to ease escape. The influenza A virus exhibit neuraminidase protein, which directly attaches to the lysosome-associated membrane proteins (LAMPs), resulting in the glycosylation of LAMPs, interruption lysosome integrity, and ultimately cause cell death [69] . The SARS-CoV-2 virus also uses enzymes of the host as a receptor for internalization; example angiotensin-converting enzyme 2 (ACE2) and aminopeptidase N (APN). The ACE-2 is a mono-carboxypeptidase, which hydrolyses angiotensin II, in large quantities present on the lung surface. The substitution of an amino acid J o u r n a l P r e -p r o o f sequence of residues between 505 and 323 with a chain of SARS-CoV receptor-binding domain allocates human ACE2 receptor utilization [69] . Several coronavirus species like CCoV, FCoV, and HCoV-229E all make use of the protein aminopeptidase N of the host as a receptor [70] .

Moreover, some respiratory viruses adopt other strategies to enter the host cell. A low acidic pH is not enough to make an entry inside the cell membrane. However, the endosomal proteases trigger the fusion of the virus with the membrane is also essential [71] . 

To escape from recognition by host immune system virus develop another strategy that is by continuous mutation of surface glycoprotein known as antigenic drift or by creation of new subtypes of these glycoprotein termed as antigenic shift [72] . For instance, influenza A virus evolved with antigenic glycoproteins hemagglutinin (HA) and neuraminidase (NA) (antigenic drift) whereas evolution of novel subtypes of hemagglutinin is also reported (antigenic shift).

Moreover, the newly emerged SARS-CoV-2 also displayed modified spike proteins on its surface and notable deviation in receptor binding domain of S-glycoprotein. Both antigenic shift and drift are major cause of epidemic outbreaks and also is the biggest hurdle in vaccination development against these viruses [73] . 

Several antiviral agents restrain the budding event and release of virion of many respiratory viruses. For instance, for the treatment of influenza A virus inhibitors developed are M2 inhibitors and neuraminidase inhibitors (NAIs). The M2 inhibitors hinder the budding event of the influenza A virus and it is a matrix protein that mediates ion channel responsible for uncoating, acidification of vacuoles, and assembly of the virus [74] . Further, the M2 proteins modify the membrane bending at the neckline of the budding virus to brace the pinching off from the membrane and begin the release of the new virion [80] . The M2 inhibitors approved for the treatment of influenza are rimantadine and amantadine. Cyclosporin A also inhibits the proliferation of the influenza virus by impeding the budding or assembly of the virus [81] .

Another treatment therapy for influenza is NAIs, which block the active site of neuraminidase; consequences are residues of non-cleaved sialic acid present on virus envelope and the host cell. This uncleaved sialic acid attaches to the HA resulting in its aggregation on the host cell membrane and decrease the quantity of virion release. These drugs are approved for human use is peramivir, laninamivir, oseltamivir, and zanamivir [82] . Oseltamivir can be administered orally, whereas zanamivir is a dry powder administered by oral inhalers. However, peramivir approved by FDA as NAIs in 2014 and the only drug administered by I.V. route.

Laninamivir is recently approved, long-circulating NAI, and given by dry powder inhaler. The emergence of influenza strains resistant to these NAIs can be a significant confront to antiviral treatment in the future [83] . Furthermore, nitazoxanide is a broad-spectrum antiviral and in vitro found active against both DNA and RNA viruses [84] . Leptomycin-B is a potent inhibitor of Crm1-dependent export, which regulates the event of trafficking of vRNPs to the cytoplasm and their assembly resulting in inhibition of virion replication [85] .

The NAIs. Favipiravir is a broad-spectrum antiviral drug currently repurposed and approved for the treatment of Covid-19 [86] . Pimodivir is also an inhibitor of non-nucleoside polymerase and in the phase-III stage of a clinical trial against the influenza virus. Another molecule ALS-008176

and PC 876 is in the phase-II clinical trials that inhibits polymerase enzyme of human respiratory syncytial virus [82] .

Ribavirin is a potential inhibitor of inosine 5'-monophosphate dehydrogenase. This enzyme plays an essential role in the synthesis of viral RNA and the biosynthesis of guanosine-5'-triphosphate. The previous studies proved that aerosolized ribavirin shows good inhibitory activity against influenza virus and RSV as compared to orally administered drugs. However, the utility of ribavirin is holding back due to the toxicity of the drug [87] .

A few novel drugs, which are in the pipeline specifically, inhibit viral capsid protein resulting in inhibition of virus replication. Pleconaril is an anti-human rhinovirus drug J o u r n a l P r e -p r o o f exclusively binds to the viral capsid [88] . Vapendavir is another oral antiviral agent that attaches to the HRV VP1 capsid protein and stops the release of the genome of the virus into the host cell.

Rupintrivir is another molecule, which is a protease inhibitor and exhibit in vitro efficacy against HRVs.

The inhibition of viral internalization shows potential approach to form new antiviral.

The 

The In addition to that, various monoclonal antibodies also developed and studied for the inhibition of viral attachment to cells. Palivizumab and motavizumab have been protecting participants from infection caused by HRSV. However, the incoherent clinical data and the skyscraping price of these biologics can also be difficult for the treatment of these infections.

An additional potential approach to reduce viral replication is by focusing on the intracellular pathways instead of directly aiming at viral proteins. Several signaling pathways Protein Kinase C (PKC) or phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (Akt), Rapidly Accelerated Fibrosarcoma (Raf)/ mitogen-activated protein kinase MEK/ extracellular-signal-regulated kinase (ERK), and NF-κB may be a prospective target to develop antiviral therapies.

The antiviral treatment therapy discussed in the above section exhibit several challenges like targeting specifically to the virus life cycle, the short half-life of drugs, less solubility or permeability, and low bioavailability, and drug-related toxicity or adverse drug reactions [94] .

The main confront is the emergence of drug resistance viral species. Currently, due to all these challenges, the world is facing a pandemic situation caused by a novel coronavirus and claimed numerous lives. Nanomedicine becomes apparent as one of the most promising technologies because of its ability to combat against these viral infections efficiently, tackling the limits of conventional therapies [94] . Various nanoformulations for antiviral drugs, including solid lipid nanoparticles, polymeric nanoparticles, liposomes, dendrimers, micelles, self-assembled nanoemulsions, and cyclodextrins have been studied (Fig. 4) [96] , [97] , [98] , [99] , [100] , [101] , [102] 

Nanoparticles (NPs) are colloidal particles that exhibit size <1 micron in diameter and can be generated by using inorganic materials, lipids, proteins, and polymers. It can be fabricated in two types i.e. matrix-like and capsule-like known as nanospheres and nanocapsules, respectively. In matrix type, the drug is uniformly dispersed or physically attaches within the nanospheres of size other antiviral agents like oseltamivir, ribavirin, zanamivir, amantadine, and arbidol were studied against H1N1 infection and revealed less toxicity in association with good activity [105] , [106] , [107] .

Silver nanoparticles (AgNPs) loaded with oseltamivir revealed remarkable inhibition against H1N1 infection and less toxicity [108] . Similar group developed zanamivir loaded AgNPs against H1N1 influenza virus infection. Curcumin loaded AgNPs were studied and found efficacious against respiratory syncytial virus infection [109] . PEGylated zinc oxide nanoparticles were studied and indicated against H1N1 influenza virus infection [110] .

Polymeric nanoparticles are colloidal particles, in general less than 500 nm in size, and are fabricated by using biodegradable and biocompatible polymers may be natural or synthetic origin. The antiviral drugs are adsorbed, entrapped or covalently adhered. The polymeric nanoparticles are prepared by several reported techniques and based on properties of drugs, size and shape of nanoparticles required these methods were used [111] . Polymeric NPs can be easily superior tissue distribution and high lymphatic system uptake and reduced first-pass metabolism.

SLNs were investigated against influenza viral infection [113] . Another group also reported SLNs of zanamivir which revealed good entrapment efficiency [114] .

Carbon-based nanocarriers present graphene, fullerenes, and carbon nanotubes for the delivery of antiviral drugs. respiratory syncytial virus infection [116] . Further, copper-graphene nanocomposite was developed and showed antiviral activity against the influenza virus. This copper-graphene nanocomposite inactivates the virion particles only within 30 minutes of pre-incubation. Hence, interfere with the entry of these virion particles into the host cell [117] . Graphene silver nanoparticles nanocomposites were developed and assessed against non-enveloped viruses, feline coronavirus (FCoV), and infectious bursal disease virus. The results showed that this nanocomposite inhibits 25% of infection by coronavirus [118] .

Fullerenes are one of the allotropes of carbon nanostructures and also known as a buckyball.

They are first invented highly symmetric carbon-based nanostructures and gained attention for the delivery of antiviral molecules [119] . Fullerenes are consisting of carbon atoms figuring a spherical hollow cage of nanosize. They have distinct physicochemical features like less toxicity, free radical scavenging, and the enormous capacity of derivatization due to their unique structure. It has been extensively utilized for the delivery of drugs as well as their inherent antimicrobial and antiviral activity.

Some studies intended to screen these fullerene derivatives against respiratory viral infections. Fullerene derivate tested in vitro for inhibition of acid polymerase (PA) endonuclease.

The PA stands for the subunit of influenza A RNA polymerase that shows endonuclease action.

The study revealed eight fullerene derivatives that illustrated endonuclease inhibition action. Fullerene-(tris-aminocaproic acid) hydrate was designed, and their activity against the respiratory syncytial virus was studied [122] . Fullerene modified with thiosialosyl-a (2,6)galactose disaccharide was synthesized and investigated for interaction with influenza viral proteins HA and NA. Results of this study, revealed that these fullerene derivatives target NA to J o u r n a l P r e -p r o o f some extent, but did not aim HA [123] . [125] .

MWNTs tagged with Protoporphyrin IX (PPIX) were developed as a potent antiviral to combat the influenza A virus [117] . During this photodynamic therapy, in which Influenza A/X-31 (H3N2) become inactivated after exposure to visible light. The inactivation process includes fissure of RNA and RNA-protein bond and protein oxidation due to reactive oxygen species generated by PPIX. In another study, SWCTs explored for modulating pulmonary immune responses and enhance influenza A virus titer in mice. The study confirmed that SWCNT increases influenza A virus titers in vivo with exacerbation of inflammation in lung tissues and mechanisms pointing towards modulation of key antiviral and inflammatory markers [126] .

These nanostructures also showed antiviral activity against the respiratory syncytial virus.

Micelles are colloidal structures (usually 5 nm to 100 nm) generated by amphiphilic molecules or copolymers, consist of hydrophobic and hydrophilic regions. They interact with water and instinctively form micelles at certain temperatures and concentrations. These resides inside the macrophages. However, liposomes utilization is very limited due to instability in vitro (storage and administration) as well as in vivo (protein interaction), less drug loading efficiency, and high development cost [129] .

Interestingly, some lipids have the potential to act against the respiratory syncytial virus.

Therefore, few studies illustrate the formation of liposomes by using these lipids and exploring them for drug delivery or vaccine development against RSV. Numata et al. cited inactivation of RSV is achievable by the surfactant lipid phosphoinositol (PI) [130] . Furthermore, they explained that PI lipids prevent the RSV attachment with cell but do not act as virucidal. In earlier findings, researchers have described the anti -RSV activity of fatty acids and glycerides as well. One review article also discussed the potential of liposomes as a carrier or nanovaccine against RSV [131] . Inhalable aerosolized liposomes are attached to α-gal/sialic acid design. The influenza virus attaches to sialic acid epitopes on α-gal/SA liposomes. Results trigger innate J o u r n a l P r e -p r o o f anti-Gal antibody binding to α-gal epitopes on α-gal/sialic acid liposomes and stimulate the complement system resulting in the triggering of macrophages. The macrophages engulf the influenza virus bound to α-gal/SA liposomes after contacting between anti-Gal antibody and Fcreceptors on macrophages [132] . Liposomes of phosphatidylserine species, 1-stearoyl-2arachidonoyl-sn-glycero-3-phospho-L-serine were fabricated and targeted to toll-like receptors of human rhinoviruses [133] .

Cyclodextrins (CDs) are cyclic oligosaccharide derivative of starch, in which six to twelve α-D-glucopyranose molecules are bonded by α1-4 linkages. They are bucket-shaped due to the arrangement of glucopyranose molecules. This bucket-shaped structure represents hydrophobic core, hydrophilic edges with -OH functional groups. The commonly used CDs are α-CDs, β-CDs, and γ-CDs, holding 6, 7, and 8 glucopyranose units, respectively. These CDs possess unique features to form complexes with inorganic and organic lipophilic molecules.

Cyclodextrins are chiefly used in the pharmaceutical region to improve aqueous solubility, protect the drugs, increase bioavailability and stability of antiviral agents. Modified CD derivatives prepared by enzymatic and chemical treatment of macrocycle 1 of CDs. These CD derivatives self-assemble in the aqueous phase and offer a variety of shapes like nanorods, nanospheres, micelles, vesicles, liquid-crystalline arrangement, and nanoparticles ranging 30-500 nm for drug delivery purpose [134] .

Currently, there is an urgent need to search for efficient therapy for the covid-19. Many antivirals repurposed (remdesivir, lopinavir + ritonavir, oseltamivir, and nitazoxanide) to combat against novel coronavirus. These antiviral agents encounter a common problem of low aqueous solubility. Hence, hydroxypropyl beta-cyclodextrins (HPβCD) that entraps remdesivir and lopinavir were tested against novel coronavirus. In another study, modified CDs with mercaptoundecane sulfonic acids were developed and studied against many viruses like respiratory syncytial virus. Results revealed that these modified CDs are effective in vitro against RSV in respiratory culture models [135] . Kusakabe et al. reported usage of HPβCD as an adjuvant with hemagglutinin and inactivated whole-virion influenza for influenza vaccine in mice. They found that immunization resulted in secretion of antigen-specific IgA and IgGs in the airway mucosa and the serum as well. Hence it was showed that HPβCD might be a promising mucosal adjuvant for influenza vaccine [136] . In another study, CDs derivatives were generated J o u r n a l P r e -p r o o f and screened for anti-influenza action. Cell-based assay revealed that they exhibit inhibition activity against the influenza virus and block the entry of the virus into the host cell [137] .

Recently, the combination of ritonavir with lopinavir repurposed and found efficacious for novel coronavirus. These antiviral drugs were loaded inside γ-CD and HPβCD for the enhancement of solubility [138] . Remdesivir is an insoluble drug, therefore, loaded in CDs for improvement of solubility and stability. Nitazoxanide is another repurposed drug against novel coronavirus, entrapped in CDs [139] .

Dendrimers are highly-branched, symmetrical, monodispersed 3-D nanosystems (2-100 nm).

They generally have a symmetric interior core, which is created by repetitive building units, whereas the outer core exhibit enormous functionalities. The flexible and empty space inside the dendrimers eases the loading of drugs, and the external functionalities conjugate the molecules/drugs via covalent bonds or electrostatic interaction. Dendrimers purposes several benefits like tremendous uptake by cells, enhance circulation time, improve stability and solubility, and targeted delivery. The functionalization of dendrimers is primarily by conjugation of three types of particle anionic groups, peptides, and carbohydrates. Noteworthy, these dendrimers acquire natural antiviral and antimicrobial properties. Successfully, one dendrimer formulation reached up to phase I/II clinical trials that are vivaGel. It is a poly-L-lysine dendrimer modified with naphthalene disulfonate groups for a vaginal microbicidal activity [140] .

Gunther et al. developed poly(amidoamine) (PAMAM) dendrimers functionalized with 3′sialyllactose (3SL) or 6′-sialyllactose (6SL) and evaluated their prospective to inhibit avian and human influenza virus strains. Hemagglutination inhibition assay confirmed that human influenza strains are restrained by (6SL) more as compared to 3SL modified dendrimers [141] .

The carbosilane dendrimers functionalized with hemagglutinin binding peptide (sialic acidmimic peptide, Ala-Arg-Leu-Pro-Arg) were designed and assessed for anti-influenza activity [142] . In another study, polyvalent sialic acid -conjugated PAMAM dendrimer was synthesized and assessed against strains of influenza A virus. In vivo results confirmed that these dendrimers prohibited infection by an H3N2 subtype in a murine influenza pneumonitis model [143] .

Carbosilane dendrimers functionalized with sialyl lactose moieties (Neu5Acα2→3Galβ1→4Glc)

were synthesized and evaluated for anti-influenza virus activity. Dendrimers also studied in J o u r n a l P r e -p r o o f nanovaccine formulation; adjuvant free, single-dose dendrimer nanoparticle incorporating mRNA replicons evaluated to produce protective immunity against Toxoplasma gondii, Ebola virus, and H1N1 influenza. The results suggest that they have a high potential to develop an adjuvant free vaccine [144] .

Nanoemulsions mainly comprise of oil, water, co-surfactants, and surfactants. They are thermodynamically single-phase systems with the globule size of 20-200 nm. Nanoemulsions exhibit advantages like greater drug loading capacity, improve solubility, enhanced absorption, and bioavailability, higher lymphatic uptake, and increase residence time in gastrointestinal tract.

Therefore, nanoemulsion loaded with antiviral agents enhances the solubility of these drugs.

Self-nano emulsifying drug delivery systems (SNEDDS) are a different category of lipidic systems [145] . responses and TH1/TH17 cellular immunity consequential to protect against a range of respiratory viral infections [148] . Nanoemulsion enclosing the recombinant H5 adjuvant was administered intranasally in mice against the avian influenza virus [14] . 

Currently, we all are in the middle of a pandemic situation due to novel coronavirus -2 officially named severe-respiratory syndrome coronavirus-2 (SARS-Cov-2 [158] , [159] , [160] , [161] . In this section, nanocarriers under investigation for vaccine development and antiviral compounds delivery against SARS-CoV-2 were discussed.

The In another study, McKay and colleagues presented SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle (LNP) as an intranasal vaccine. Results confirmed that specific antibody titers for SARS-CoV-2 were observed and this vaccine is harmless [159] , [164] . On the other hand, some adjuvants specifically developed and licensed for vaccine development for covid -19 example cytosine and guanine with phosphodiester backbone (CpG 1018,Dynavax), adjuvant system 03 (ASO3, GSK), and MF59 (Sequirus) [164] . Table 5 explained several covid-19 vaccine under clinical trial, nanotechnology used for fabrication, and major key findings of vaccine. hydroxychloroquine. This formulation strategy could also be advantageous for SARS-CoV-2 treatment, and act dually o viral load and pulmonary fibrosis [126] . Another study presented development of poly (lactic-co-glycolic acid) and polyethylene copolymer nanoparticles for encapsulation of combination antiretroviral therapy that is ribavirin and DX600 (specific, potent and novel peptide inhibitor of ACE2) could be promising treatment therapy for SARS-CoV-2.

However, metallic nanoparticles (silver, zinc, and copper) also revealed antiviral activity against coronaviruses, which exhibit alike characteristics with SARS-CoV-2.

The toxicity and inability to treat viral/resistant viral infection, there is an increasing need Syncytial Virus by inhibiting viral attachment, internalization and stimulate INF-beta secretion [176] .

However, many studies are of preliminary level, thus further studies with isolated compounds responsible for activity, study of interplay of additional compounds (present in same extract or other natural product) for presence of any synergy, characterization of mechanism and toxicity, and co-activity with the currently available promising drugs/therapy. Furthermore, it is largely believed in scientific community and proved that natural products have potential to be explored further and may certainly produce more precise and specific molecules to be used as antiviral therapeutics.

The alarming rise of respiratory viral infections, drug-resistant strains of viruses, and high zoonosis posing need of newer technological solutions in the field of medicine and presently, the covid-19 pandemic had proven that. These respiratory viral infections impacting socioeconomic J o u r n a l P r e -p r o o f and major health crisis globally. The industry and academia all over the world at present working very furiously to find solution of these respiratory viral diseases. Nanotechnology has transformed whole world by proposing several innovative approaches to address many problems, specifically in healthcare sector. The application of nanocarriers or nanotechnological tools to deal with these emerging respiratory viral infections is currently a good strategy. We have summarized in this review the respiratory viruses, their tactics to survive inside cells, transmission mode, and nanocarriers under the umbrella of nanotechnology. Further, the few nanocarriers under trials for SARS-CoV-2 treatment is also overviewed.

Future demands the development of novel antiviral therapeutics, theranostics, and nanocarriers to combat against these deadly viruses. Further, basic research by using computer aided drug discovery to find new drugs and computational simulation to study interaction between virus and nanoparticles is necessary. As discussed above, many nanotechnological approaches to deal with SARS-CoV-2 are also under progress like vaccine development, and therapeutic delivery.

However, nanotechnological strategies also applied for diagnostics, PPE kits, and mask development against covid-19. Several new approaches nanodiamonds, nanotraps, nanofibers, nanoherbal formulations, and nanorobots are also under investigation against HIV and influenza, and may be extended to other viruses. It can be endorsed to enlarge research on this theme to improve the current knowledge, therapy and to avoid resistance of these viruses.

However, major barriers in advancement of these nanocarriers are complication in characterization, construction, large-scale production, and lack of regulatory guidelines. Further, the nanotoxicity study of these carriers is supreme requirement to prove safety. However, the continuous emergence of these respiratory viruses need prompt advancements to control and manage viral infections more efficiently.

Forum of International Respiratory Societies

severe-dengue#:~:text=The number of dengue cases

Ebola virus disease

World Heal. Organ

:~:text=The 1968 pandemic was caused,United States in

Control Prev

Drug resistance in influenza A virus: the epidemiology and management

Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection

Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines

Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health

Seasonal and pandemic influenza preparedness: science and countermeasures

Analysis of the complete genome sequences of human rhinovirus

Human rhinoviruses

A study of the genetic variability of human respiratory syncytial virus (HRSV) in Cambodia reveals the existence of a new HRSV group B genotype

Human Respiratory Syncytial Virus: Infection and Pathology

Human parainfluenza virus infection in severe acute respiratory infection cases in Beijing, 2014-2016: A molecular epidemiological study

Human metapneumovirus: A new player among respiratory viruses

The repertoire of adenovirus in human disease: The innocuous to the deadly

Nonstructural Protein NP1 of Human Bocavirus 1 Plays a Critical Role in the Expression of Viral Capsid Proteins

Human bocavirus: Current knowledge and future challenges

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information

Chapter Four -Structural insights into coronavirus entry

COVID-19) Dashboard, World Heal. Organ

Aerobiology and Its Role in the Transmission of Infectious Diseases

Transmission routes of respiratory viruses among humans

Relevance of SARS-CoV-2 in food safety and food hygiene: potential preventive measures, suggestions and nanotechnological approaches

Virus entry at a glance

Virus entry by endocytosis

Virus entry by macropinocytosis

Virus entry: Molecular mechanisms and biomedical applications

Mechanisms of clathrin-mediated endocytosis

The human polyomaviruses

Multifaceted functions of host cell caveolae/caveolin-1 in virus infections

The Rab5 effector Rabankyrin-5 regulates and coordinates different endocytic mechanisms

Defining macropinocytosis

Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway

Come in and take your coat off -how host cells provide endocytosis for virus entry

Respiratory syncytial virus persistence in macrophages upregulates fcgamma receptors expression

Lymphocytic choriomeningitis virus uses a novel endocytic pathway for infectious entry via late endosomes

Confined no more: Viral mechanisms of nuclear entry and egress

Environmental factors affecting the transmission of respiratory viruses

Influenza A virus is transmissible via aerosolized fomites

Viral escape from endosomes and host detection at a glance

Capsid Protein VP4 of Human Rhinovirus Induces Membrane Permeability by the Formation of a Size-Selective Multimeric Pore

Parainfluenza viruses

Mode of Parainfluenza Virus Transmission Determines the Dynamics of Primary Infection and Protection from Reinfection

Human metapneumovirus -what we know now

Human metapneumovirus in adults

Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention

Adenovirus endocytosis

Clathrin-Associated Endocytosis as a Route of Entry into Cells for Parvoviruses

Structural proteomics of the SARS coronavirus: A model response to emerging infectious diseases

Mechanisms of coronavirus cell entry mediated by the viral spike protein

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

The influenza hemagglutinin fusion domain is an amphipathic helical hairpin that functions by inducing membrane curvature

SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

Viral mechanisms of immune evasion

Endosomal escape pathways for delivery of biologicals

Endosomal escape: A bottleneck in intracellular delivery

The conserved N-terminus of human rhinovirus capsid protein VP4 contains membrane pore-forming activity and is a target for neutralizing antibodies

Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives

Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies

Proteolytic processing of middle east respiratory syndrome coronavirus spikes expands virus tropism

Novel insights into proteolytic cleavage of influenza virus hemagglutinin

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses

Antivirals for Respiratory Viral Infections: Problems and Prospects

Opening of Size-Selective Pores in Endosomes during Human Rhinovirus Serotype 2 In Vivo Uncoating Monitored by Single-Organelle Flow Analysis

The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication

Coronaviruses-drug discovery and therapeutic options

Endosomal Proteolysis by Cathepsins Is Necessary for Murine Coronavirus Mouse Hepatitis Virus Type 2 Spike-Mediated Entry

Sructure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor

Influenza virus assembly and budding

Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways

Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and Middle East respiratory syndrome coronavirus infections

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A doubleblind, randomized, noninferiority clinical trial

Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?

Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA

Favipiravir: A new and emerging antiviral option in COVID-19

A new era for ribavirin aerosols to treat respiratory syncitial virus infections in immunocompromised patients?

In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses

Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein

Anti-Influenza Treatment: Drugs Currently Used and Under Development

The actin cytoskeleton inhibits pore expansion during PIV5 fusion protein-promoted cellcell fusion

Entry Inhibitors: Efficient Means to Block Viral Infection

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children

Nanotechnology-based antiviral therapeutics

Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections

Formulation and evaluation of β-cyclodextrin-mediated inclusion complexes of isoniazid scaffolds: molecular docking and in vitro assessment of antitubercular properties

An Introduction To Liposome Processing For Drug Delivery

Nanostructured lipid carriers: versatile oral delivery vehicle

Applications of Polymeric Nanoparticles in Food Sector

Liposomes and Lipid Nanoparticles as Delivery Vehicles for Personalized Medicine

Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections

Biomedical potential of actinobacterially synthesized selenium nanoparticles with special reference to antibiofilm, anti-oxidant, wound healing, cytotoxic and anti-viral activities

Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus

The inhibition of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with zanamivir

Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway

Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways

Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection

Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine

Nanoparticles: A Novel Approach to Target Tumors

Polymeric Nanoparticles for Drug Delivery

Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model

Preparation and evaluation of zanamivir-loaded solid lipid nanoparticles

Comprehensive Review on Graphene Oxide for Use in Drug Delivery System

Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection

Development of a copper-graphene nanocomposite based transparent coating with antiviral activity against influenza virus

Carbon-based antiviral nanomaterials: Graphene, C-dots, and fullerenes. A perspective

Fullerene-based delivery systems

Anti-Influenza Activity of C60 Fullerene Derivatives

The antiviral effect of fullerene-liposome complex against influenza virus (H1N1) in vivo

Antiviral Activity of Fullerene-(Tris-Aminocaproic Acid) Hydrate Against Respiratory Syncytial Virus in HEp-2 Cell Culture

Synthesis of a cluster-forming sialylthio-d-galactose fullerene conjugate and evaluation of its interaction with influenza virus hemagglutinin and neuraminidase

Applications of carbon nanotubes in drug delivery

Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues

Cholesterol-modified Hydroxychloroquine-loaded Nanocarriers in Bleomycin-induced Pulmonary Fibrosis

Polymeric micelles for drug delivery

Reverse micelleencapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice

Trends and developments in liposome drug delivery systems

Phosphatidylinositol inhibits respiratory syncytial virus infection

Liposomes: a promising carrier for respiratory syncytial virus therapeutics

Inhalation of α-gal/sialic acid liposomes: a novel approach for inhibition of influenza virus infection?

Human rhinovirus-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes

Pharmaceutical Applications of Cyclodextrins . 1 . Drug Solubilization and Stabilization

Modified cyclodextrins as broad-spectrum antivirals

Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection

Inhibition of influenza virus infection by multivalent pentacyclic triterpene-functionalized per-O -methylated cyclodextrin conjugates

Complexation approach for fixed dose tablet formulation of lopinavir and ritonavir: an anomalous relationship between stability constant, dissolution rate and saturation solubility

The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2

Applications of dendrimers in drug delivery agents, diagnosis, therapy, and detection

Antiviral potential of 3′-sialyllactose-and 6′-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses

Synthesis and Influenza Virus Inhibitory Activities of Carbosilane Dendrimers Peripherally Functionalized with Hemagglutinin-Binding Peptide

Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

Nanoemulsions in drug delivery: formulation to medical application

Engineering of Nanoemulsions for Drug Delivery

Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions

Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant

Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with zanamivir through p38 and JNK signaling pathways

Inhibition of H1N1 influenza virus-induced apoptosis by selenium nanoparticles functionalized with arbidol through ROS-mediated signaling pathways

Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice

Preparation of Fullerenes and Fullerene-Based Materials, Solid State Phys

Single-walled carbon nanotubes modulate pulmonary immune responses and increase pandemic influenza a virus titers in mice

Preparation of multifunctional polymeric micelles for antiviral treatment

Anti-RSV peptideloaded liposomes for the inhibition of respiratory syncytial virus

Prevention of influenza pneumonitis by sialic acid-conjugated dendritic polymers

Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge

Recent Advances on Nanotechnology-Based Strategies for Prevention, Diagnosis, and Treatment of Coronavirus Infections

Nanotechnology Responses to COVID-19

Engineered nanomaterials as fighters against SARS-CoV-2: The way to control and treat pandemics

Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents

A review on drug repurposing applicable to COVID-19

COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management

Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines

An Update on Current Therapeutic Drugs Treating COVID-19

Improving encapsulation of hydrophilic chloroquine diphosphate into biodegradable nanoparticles: A promising approach against herpes virus simplex-1 infection

Natural Products as Antiviral Agents

Antiviral Evaluation of Herbal Drugs

Natural and Nature-Derived Products Targeting Human Coronaviruses

Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Pati, NCT04705753

Antiviral Potential and Molecular Insight into Neuraminidase Inhibiting Diarylheptanoids from Alpinia katsumadai

Antiviral natural products and herbal medicines